Skip to content 
The future of hepatitis C in public health
There are still more strategies to be tested, and future studies may include virus-like particle-based vaccines, which work similarly to vector vaccines. It is also possible that further studies develop a vaccine adjuvant to strengthen the effectiveness of current variants.
We have running different hepatitis C vaccine trials with promising results. Even more, approaches may be explored in the future to obtain an accurate and fully-functioning vaccine. There is current expectancy on the release of protease inhibitors in the near future, which will influence the therapeutic process in hepatitis C but only for genotype 1. Thus, there’s still a need for hepatitis C vaccines to reduce the impact of the disease and its consequences.
References
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006). Treating viral hepatitis C: efficacy, side effects, and complications. Gut, 55(9), 1350-1359.
Simmonds, P. (1999). Viral heterogeneity of the hepatitis C virus. Journal of hepatology, 31, 54-60.
Maher, L., White, B., Hellard, M., Madden, A., Prins, M., Kerr, T., & Page, K. (2010). Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine, 28(45), 7273-7278.
Habersetzer, F., Zarski, J. P., Leroy, V., Maynard-Muet, M., Bronowicki, J. P., Feray, C., … & Honnet, G. (2009). 42 A NOVEL VECTORIZED HCV THERAPEUTIC VACCINE (TG4040): RESULTS OF A PHASE I STUDY IN NAIVE PATIENTS CHRONICALLY INFECTED BY HCV. Journal of Hepatology, 50, S18.
